5 recruiting, 3 not yet recruiting, 1 active not recruiting, 1 completed. 11 Phase 2, 8 Phase 1.
Follow Evopoint Biosciences Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of XNW5004 Tablets in Advanced Prostate Cancer XNW5004 1200 mg BID in Combination with Abiraterone plus Prednisone, XNW5004 1200 mg BID in Combination with Docetaxel plus Prednisone, XNW5004 800 mg or 1200 mg (1:1 randomization), PO, BID; Abiraterone 1000 mg PO, taken on an empty stomach at least 1 hour before and at least 2 hours after a meal, QD; plus Prednisone 5 mg PO BID - Advanced Prostate Cancer | Phase 2 | Not yet recruiting | Evopoint Biosciences Inc. | 242 | 2026-07-13 | 2026-07-28 |
| Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma XNW5004 tablets - Follicular Lymphoma, Grade 1, Follicular Lymphoma, Grade 2 | Phase 2 | Recruiting | Evopoint Biosciences Inc. | 65 | 2026-02-14 | 2026-04-22 |
| A Phase I/II Study to Evaluate XNW34017 in Patients With Advanced or Metastatic Solid Tumor XNW34017 - Advanced Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | Evopoint Biosciences Inc. | 150 | 2026-01-31 | 2026-01-08 |
| Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma XNW5004 combined with CHOP (incremental), XNW5004 combined with CHOEP (incremental), XNW5004 combined with CHOP (extended) - Non-hodgkin Lymphoma, Peripheral T-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Evopoint Biosciences Inc. | 176 | 2025-08-15 | 2026-07-29 |
| A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment XNW29016 - Tumor, Solid | Phase 1 / Phase 2 | Recruiting | Evopoint Biosciences Inc. | 132 | 2025-04-11 | 2026-10-16 |
| To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma XNW5004 tablets - Relapsed/Refractory Peripheral T Cell Lymphoma | Phase 2 | Not yet recruiting | Evopoint Biosciences Inc. | 50 | 2024-11-01 | 2024-11-25 |
| Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments XNW28012 - Advanced Solid Tumors, Pancreatic Carcinoma | Phase 1 / Phase 2 | Recruiting | Evopoint Biosciences Inc. | 350 | 2023-12-01 | 2026-04-15 |
| Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19) XNW5004, KEYTRUDA® (pembrolizumab) 25 mg/mL Solution for Injection - Carcinoma, Squamous Cell Carcinoma of Head and Neck | Phase 1 / Phase 2 | Terminated | Evopoint Biosciences Inc. | 12 | 2023-09-20 | 2026-07-23 |
| XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies. XNW27011 - Pancreatic Adenocarcinoma Metastatic, Lung Cancer (NSCLC) | Phase 1 / Phase 2 | Active not recruiting | Astellas Pharma Global Development, Inc. | 240 | 2023-07-27 | 2026-08-11 |
| Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer XNW5004, enzalutamide - Metastatic Castrate-Resistant Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer) | Phase 1 / Phase 2 | Recruiting | Evopoint Biosciences Inc. | 307 | 2023-04-19 | 2026-10-20 |
| To Evaluate a Phase I/II Clinical Study of XNW5004 Tablets in Patients With Relapsed/Refractory Advanced Tumors XNW5004 tablets - Advanced Tumor, Lymphoma | Phase 1 / Phase 2 | Completed | Evopoint Biosciences Inc. | 120 | 2021-08-03 | 2026-10-20 |
Carcinoma, Non-Small-Cell Lung (2) · Lymphoma, T-Cell, Peripheral (2) · Ovarian Neoplasms (2) · Uterine Cervical Neoplasms (2) · Biliary Tract Neoplasms (1) · Carcinoma (1) · Carcinoma, Transitional Cell (1) · Lung Neoplasms (1) · Lymphoma (1) · Lymphoma, Follicular (1) · Lymphoma, Non-Hodgkin (1) · Neoplasms (1) · Pancreatic Neoplasms (1) · Prostatic Neoplasms (1) · Small Cell Lung Carcinoma (1)
Prednisone (2) · enzalutamide (2) · BID protein, human (1) · Cyclophosphamide (1) · Docetaxel (1) · Doxorubicin (1) · Etoposide (1) · Injections (1) · Lead (1) · Postprandial Period (1) · Random Allocation (1) · Solutions (1) · Vincristine (1) · abiraterone (1) · pembrolizumab (1)
China (9)
D Ye, M.D. (1) · Li Zhang, M.D. (1) · QI Junyuan (1) · Qiu Lugui (1) · Yuqin Song, PhD (1)